This overview is generated using artificial intelligence based on information available
on the platform’s project page and publicly accessible data. It is provided for
informational purposes only and does not constitute investment advice, financial
guidance, risk assessment, or project scoring. Platforms and project owners are not
involved in the creation, review, or endorsement of this content.
AI project overview
Condensed summary based on project data
<h1><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">IRUBIS GmbH — Crowdfunding Investor Memo</span></span></h1>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><em>Real-time mid-infrared monitoring to bring biopharmaceutical drugs to market faster.</em></span></span></p>
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Sector: Medtech / bioprocess analytics (PAT) · Stage: Series A · HQ: Munich, Germany · Raise: €800K (of a larger Series A round)</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; width:200px">
<p style="text-align:center"> </p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:424px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong>Why this score:</strong></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">AI SCORE</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Credible team: CEO Matthias Eggers led m2p-labs through its Beckman Coulter / Danaher acquisition — a directly relevant exit, independently verified.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:28.0pt"><span style="color:black">66 / 100</span></span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">Real product with external proof: 20 Monipa units in the field, a published AGC Biologics case study, and an independent ReciBioPharm testimonial.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:200px">
<p style="text-align:center"><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">⭐ Moderate</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">But traction is still thin (a “manageable number” of reference customers, artisanal production) and the financial plan implies a ~40x revenue ramp by 2030 that is unvalidated.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faeeda; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:200px">
<p style="text-align:center"> </p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:424px">
<ul>
<li><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif">The retail instrument is investor-unfriendly: a profit participation certificate via an SPV with no voting rights, ~20% upfront fees, a 15% carry, and no ordinary exit before FY2041.</span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#e6f1fb; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px">
<p><span style="font-size:10pt"><span style="font-family:"Times New Roman",serif"><strong><span style="color:black">ℹ️ This is not investment advice.</span></strong><span style="color:black"> </span></span></span><span style="font-size:10pt"><span style="font-family:'Times New Roman',serif"><span style="color:#000000">The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision. Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data. </span></span></span><span style="font-size:11pt"><span style="font-family:Arial,sans-serif"><span style="color:#000000"> </span></span></span></p>
</td>
</tr>
</tbody>
</table>
<h2><span style="font-size:10pt"><span st
…
Equity crowdfunding
